ImaginAb is focused on developing advanced imaging agents and radiopharmaceutical therapy products aimed at enhancing immunotherapy and patient care in oncology. They utilize minibody antibodies and related technologies for cancer diagnostics and treatment.

ImaginAb

Viewport Meta

IPhone / Mobile Compatible

Domain Not Resolving

SSL by Default

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Analytics

Content Delivery Network

Founder

Anna Wu

David Fractor

Founder and Chief Medical Officer

Robert Reiter

Vice President Business Strategy

Gareth Smith

VP, Medical Affairs

Kristin Schmiedehausen

Vice President, Global Operations | Senior Director of Clinical Development | Program Director

William Le

Director of Research - Biologics Discovery

Alessandro Mascioni

Director Business Development

Gregory Frank

Controller

Jill Durkin

Associate Director, QA

Kathleen Brady

K. Dane Wittrup

K. Leonard Judson

Peter Senter

Sanjiv Gambhir

Abbie Celniker

Valerie Calenda

Michael R. Zalutsky

Friedhelm Blobel

Anna M. Wu

Vice President, Operations

Jean Gudas

Vice President of Research and Development

Ian Wilson

Chief Executive Officer

Dan Shochat

Vice President of Manufacturing

Robert E. Reiter

Founder & Chief Medical Officer

Health Diagnostics Companies With Fewer Than 100 Employees (Top 10K)

Health Care Companies With Less Than $1B in Revenue (Top 10K)

Clinical Trials Companies With Fewer Than 1000 Employees

Biotechnology Companies With More Than $10M in Revenue

ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.

Adage Capital Management

Cycad Group

Venture Round - ImaginAb

Mérieux Equity Partners

Series B - ImaginAb

Novartis Venture Fund

Series A - ImaginAb

Inglewood

California

United States

North America

Advanced Merkel Cell Carcinoma Pipeline, FDA Approval, Clinical Trials Development and Companies (Updated)

Dual-inhibitory domain iCARs improve the efficiency of the ...

Radioactive Tracer Market Worth $54.29 Billion by 2030 ...

Antibodies and methods of making and using same

Dll3 antigen binding constructs

Mapping the immunological landscape of cancer via ...

ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with Leucid Bio

Antigen binding constructs to target molecules

ImaginAb launches trial to study neoadjuvant immunotherapy

A non-invasive imaging solution that maps the immune response by visualizing CD8 positive T-cells across the entire body, aiding in the assessment of treatment effectiveness.

Development of radiopharmaceuticals for therapy using antibody fragment platform technologies, aiming to provide targeted treatment options.

Provides support and guidance for the implementation of CD8 ImmunoPET technology in clinical trials, including partnerships with pharmaceutical and biotech companies.

HTML5

Lightbox

Vimeo

Google Fonts

Adobe Fonts

Wordpress

Google Maps API

jQuery

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 17, 2024 6:07 PM	0d488596
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 17, 2024 6:07 PM	67cf56d8
crunchbase trigger	general	Nov 17, 2024 6:07 PM	4e9c5fee
crunchbase profile	general	Nov 17, 2024 6:15 PM	b8bb4a47
li profile	general	Nov 17, 2024 6:07 PM	c589aeea
translate crunchbase fundingrounds	general	Nov 17, 2024 6:37 PM	a682353e
peers	general	Nov 17, 2024 6:07 PM	9ac15e5e
news basic	general	Nov 17, 2024 6:07 PM	2646983b
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

IMAG

COM:IMAGINAB

ImaginAb